![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: C4B |
Gene summary for C4B |
![]() |
Gene information | Species | Human | Gene symbol | C4B | Gene ID | 721 |
Gene name | complement C4B (Chido blood group) | |
Gene Alias | C4B1 | |
Cytomap | 6p21.33 | |
Gene Type | protein-coding | GO ID | GO:0002237 | UniProtAcc | P0C0L4 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
721 | C4B | S014 | Human | Liver | HCC | 8.95e-14 | 5.29e-01 | 0.2254 |
721 | C4B | S015 | Human | Liver | HCC | 5.32e-09 | 3.55e-01 | 0.2375 |
721 | C4B | S016 | Human | Liver | HCC | 2.68e-06 | 2.37e-01 | 0.2243 |
721 | C4B | S027 | Human | Liver | HCC | 2.14e-11 | 6.98e-01 | 0.2446 |
721 | C4B | S028 | Human | Liver | HCC | 3.07e-19 | 5.41e-01 | 0.2503 |
721 | C4B | S029 | Human | Liver | HCC | 8.23e-25 | 8.22e-01 | 0.2581 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00098967 | Liver | NAFLD | positive regulation of catabolic process | 108/1882 | 492/18723 | 2.68e-15 | 3.14e-12 | 108 |
GO:00421767 | Liver | NAFLD | regulation of protein catabolic process | 83/1882 | 391/18723 | 2.94e-11 | 1.01e-08 | 83 |
GO:00420607 | Liver | NAFLD | wound healing | 84/1882 | 422/18723 | 6.56e-10 | 1.37e-07 | 84 |
GO:00075994 | Liver | NAFLD | hemostasis | 49/1882 | 222/18723 | 9.23e-08 | 7.59e-06 | 49 |
GO:00075964 | Liver | NAFLD | blood coagulation | 48/1882 | 217/18723 | 1.16e-07 | 8.81e-06 | 48 |
GO:00508174 | Liver | NAFLD | coagulation | 48/1882 | 222/18723 | 2.40e-07 | 1.61e-05 | 48 |
GO:00457327 | Liver | NAFLD | positive regulation of protein catabolic process | 48/1882 | 231/18723 | 8.22e-07 | 4.45e-05 | 48 |
GO:00508787 | Liver | NAFLD | regulation of body fluid levels | 60/1882 | 379/18723 | 2.61e-04 | 4.23e-03 | 60 |
GO:0045916 | Liver | NAFLD | negative regulation of complement activation | 6/1882 | 12/18723 | 5.54e-04 | 7.46e-03 | 6 |
GO:0030449 | Liver | NAFLD | regulation of complement activation | 8/1882 | 21/18723 | 6.29e-04 | 8.21e-03 | 8 |
GO:0002921 | Liver | NAFLD | negative regulation of humoral immune response | 6/1882 | 16/18723 | 3.37e-03 | 2.93e-02 | 6 |
GO:004217612 | Liver | Cirrhotic | regulation of protein catabolic process | 181/4634 | 391/18723 | 7.94e-21 | 2.77e-18 | 181 |
GO:000989612 | Liver | Cirrhotic | positive regulation of catabolic process | 215/4634 | 492/18723 | 1.13e-20 | 3.56e-18 | 215 |
GO:004573212 | Liver | Cirrhotic | positive regulation of protein catabolic process | 112/4634 | 231/18723 | 3.89e-15 | 4.21e-13 | 112 |
GO:004206012 | Liver | Cirrhotic | wound healing | 155/4634 | 422/18723 | 2.12e-08 | 7.56e-07 | 155 |
GO:000759611 | Liver | Cirrhotic | blood coagulation | 79/4634 | 217/18723 | 8.06e-05 | 8.81e-04 | 79 |
GO:000759911 | Liver | Cirrhotic | hemostasis | 80/4634 | 222/18723 | 1.08e-04 | 1.10e-03 | 80 |
GO:005081711 | Liver | Cirrhotic | coagulation | 79/4634 | 222/18723 | 1.90e-04 | 1.76e-03 | 79 |
GO:005087812 | Liver | Cirrhotic | regulation of body fluid levels | 118/4634 | 379/18723 | 2.65e-03 | 1.55e-02 | 118 |
GO:000989622 | Liver | HCC | positive regulation of catabolic process | 335/7958 | 492/18723 | 3.83e-31 | 1.87e-28 | 335 |
Page: 1 2 3 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
C4B | SNV | Missense_Mutation | novel | c.3313N>G | p.Asn1105Asp | p.N1105D | P0C0L5 | protein_coding | tolerated(0.61) | benign(0.04) | TCGA-EO-A22U-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
C4B | SNV | Missense_Mutation | novel | c.3507N>C | p.Glu1169Asp | p.E1169D | P0C0L5 | protein_coding | tolerated(0.15) | benign(0.015) | TCGA-EO-A3AY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
C4B | SNV | Missense_Mutation | rs751412917 | c.3898C>T | p.Arg1300Cys | p.R1300C | P0C0L5 | protein_coding | tolerated(0.14) | benign(0.315) | TCGA-FI-A2D5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatinum | PD |
C4B | SNV | Missense_Mutation | c.3824N>C | p.His1275Pro | p.H1275P | P0C0L5 | protein_coding | tolerated(0.11) | benign(0.188) | TCGA-DD-A73B-01 | Liver | liver hepatocellular carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
C4B | SNV | Missense_Mutation | rs767540386 | c.3347N>T | p.Ser1116Leu | p.S1116L | P0C0L5 | protein_coding | deleterious(0) | possibly_damaging(0.511) | TCGA-69-7978-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
C4B | SNV | Missense_Mutation | rs754182832 | c.3593N>G | p.Tyr1198Cys | p.Y1198C | P0C0L5 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-22-4613-01 | Lung | lung squamous cell carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
C4B | SNV | Missense_Mutation | novel | c.3667G>A | p.Glu1223Lys | p.E1223K | P0C0L5 | protein_coding | tolerated(0.24) | benign(0.02) | TCGA-CV-5443-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | III/IV | Unknown | Unknown | SD |
C4B | SNV | Missense_Mutation | novel | c.4007N>T | p.Arg1336Leu | p.R1336L | P0C0L5 | protein_coding | deleterious(0) | possibly_damaging(0.852) | TCGA-UF-A71B-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
C4B | SNV | Missense_Mutation | rs574457656 | c.3871N>T | p.Arg1291Cys | p.R1291C | P0C0L5 | protein_coding | deleterious(0) | possibly_damaging(0.849) | TCGA-UF-A7JV-01 | Oral cavity | head & neck squamous cell carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
C4B | SNV | Missense_Mutation | novel | c.3662N>T | p.Ala1221Val | p.A1221V | P0C0L5 | protein_coding | tolerated(0.23) | possibly_damaging(0.804) | TCGA-HC-A9TH-01 | Prostate | prostate adenocarcinoma | Male | <65 | 9 | Hormone Therapy | firmagon | SD |
Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |